NCT05227651View on ClinicalTrials.gov

AK104 in Neoadjuvant Treatment of Cervical Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

February 10, 2023

Primary Completion Date

September 27, 2024

Study Completion Date

September 27, 2024

Conditions
Cervical Cancer
Interventions
DRUG

AK104

IV infusion,Specified dose on specified days

Trial Locations (1)

310022

Zhejiang Cancer Hospital, Hanzhong

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
lead

Akeso

INDUSTRY

NCT05227651 - AK104 in Neoadjuvant Treatment of Cervical Cancer | Biotech Hunter | Biotech Hunter